The problem of early diagnostics and prevention of cervical cancer is actual in Ukraine.The leading etiologic factor in the genesis of cervical neoplasia and a number of other organs is Human papillomavirus (HPV). The human papillomavirus is sexually transmitted and has high contagiosity. Cancer prevention consists in effective screening, early detection and treatment of pathological changes in the cervix. The aggressive treatment of diseases caused by (HPV) has been replaced by a tactic of a differentiated approach, taking into account to the age of the woman and her reproductive plans. The objective: was to study the efficacy and tolerability of the combined use of Proteflazid® systemically in drops form and locally in the form of suppositories for 3 months in patients with cervical intraepithelial neoplasia (CIN) of lung and moderate severity (CIN 1 and CIN 2) associated with the human papillomavirus (HPV); determination on the basis of the results of the need for further destructive treatment. Materials and methods. For the period from July 2016 to September 2017, we examined and treated 86 women with morphologically confirmed intraepithelial neoplasia of the cervix associated with HPV infection. Results. Based on the performed studies, it was found that 6 months after treatment with Proteplasid® systemically and locally for 3 months, regression of CIN was noted in 93% of patients. In all cases, a reduction in viral load of more than 2 Lg of HPV/105, which is a marker of the effectiveness of antiviral therapy, has been recorded. Six months after treatment in 84% of patients and 9 months in 88%, there was complete elimination of HPV or reduced viral load to clinically insignificant values – less than 3 Lg. Conclusion. The drug Proteflazid® suppositories and drops contributes to the elimination of human papillomavirus (HPV) and other viral-bacterial infections and reduces the risk of cervical neoplasia. Key words: cervical cancer, screening, cervical neoplasia, Human papillomavirus, viral-bacterial infections, Proteflazid®.
We give unusual observation a breast solitary fibrous tumor in a man 74 years old. The patient was undergoing an ultrasound examination, a fine-needle aspiration puncture biopsy, a histology examination after a trepan biopsy. The doctors did not give a clear answer to the surgery about the nosology of the tumor and its malignancy. A surgical intervention was performed – the removal (amputation) of the right breast with the tumor. Immunohistochemical method of tumor tissue research was applied, the final pathohistological conclusion was made – a solitary fibrous breast tumor with medium proliferation. This case once again confirms the severity of the diagnosis of tumors of such a nosology.Keywords: solitary tumor, aspiration biopsy, breast gland
The purpose of this work is to determine the optimal markers for clarifying the degree of proliferative activity in benign breast lesions, which can be used in surgical treatment planning. Materials and methods. The immunocytochemical results of tumor proliferation marker (Ki-67), cancer-embryonic antigen (CEA), matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) expression were studied in biopsy samples collected from 108 patients with benign breast lesions and 49 patients with breast cancer. Results. It was found that the proliferative processes rising was accompanied by an increase in the number of patients with expression of Ki-67 to 28.0 %, CEA to 44.0 %, VEGF to 80.0 %, and a decrease in the number of patients with MMP-9 expression from 75.0 % to 36.4 %. Among patients with breast cancer, cells expressing Ki-67 were observed in 36.8 %, MMP-9 in 20.7 %, CEA in 36.4 %, VEGF in 48.3 %. The results indicate the presence of a neoplastic potential in benign lesions and its enhancement with an increase in proliferative properties. Conclusions. This diagnostic method can be used to determine the malignant potential in benign breast lesions and for therapeutic decision making.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.